CLEVELAND CLINIC LERNER COM-CWRU
Macrophage-based Therapy and Immune Checkpoint Blockade for Glioblastoma
Macrophage-based Therapy and Immune Checkpoint Blockade for Glioblastoma is a funding opportunity from CLEVELAND CLINIC LERNER COM-CWRU, up to 368288, closing November 30, 2027.
Nov 30, 2027
(487d left)Overview
Project Summary Glioblastoma (GBM), the most lethal primary brain tumor with poor prognosis, is highly resistant to current treatments, including immune checkpoint blockade (ICB) partially due to the immune suppressive microenvironment. GBM harbors abundant tumor-associated macrophages (TAMs) that are critical immune…